Russia will charge less for its Sputnik V COVID-19 vaccine than rivals as Moscow aims to produce more than 1 billion doses at home and abroad next year, the head of Russia's sovereign wealth fund said.
Details of the exact pricing are expected later on Tuesday, but Kirill Dmitriev, head of Russia's RDIF sovereign wealth fund, told Reuters that Sputnik V would be priced significantly lower than other rivals with similar efficacy levels.
Moscow has been criticised by some scientists in the West who have accused it of cutting corners in an effort to try to rush out the Sputnik V vaccine, something that Russia has denied.
Pricing the vaccine at a lower level than competitors could help Moscow grab more market share.
Dmitriev was speaking after RDIF and the Gamaleya National Center said new clinical trial data based on 39 confirmed cases and 18,794 patients who got both shots had shown that Sputnik V was 91.4 per cent effective on day 28 and over 95 per cent effective on day 42.


Trump, Xi, Putin conclude historic meeting on Ukraine war, nuclear arms
Denmark ratifies Trump deal over Greenland
Saudi coalition reports damage after Houthi missile threat towards Riyadh
More than 47,000 evacuated in India ahead of Cyclone Akvan
Israel launches ground operation in central Gaza